Table 4.
Analysis of patients’ characteristics in CTP classification and the occurrence of hepatic adverse reactions in 74 HCC patients
| Characteristics | Patients (n) | Changes in CTP classification
|
P-value | Patients (n) | Hepatic adverse reactions
|
P-value | ||
|---|---|---|---|---|---|---|---|---|
| No | Yes | Grades 0–1 | Grades 2–3 | |||||
| Sex | 0.697 | 0.810 | ||||||
| Male | 56 | 49 | 7 | 56 | 47 | 9 | ||
| Female | 18 | 17 | 1 | 18 | 14 | 4 | ||
| Age (years) | 1.000 | 0.987 | ||||||
| ≤60 | 40 | 36 | 4 | 40 | 33 | 7 | ||
| >60 | 34 | 30 | 4 | 34 | 28 | 6 | ||
| ECOG scale | 0.911 | 1.000 | ||||||
| 0 and 1 scores | 70 | 63 | 7 | 70 | 58 | 12 | ||
| 2 score | 4 | 3 | 1 | 4 | 3 | 1 | ||
| History of hepatitis B | 1.000 | 0.745 | ||||||
| Yes | 62 | 55 | 7 | 62 | 52 | 10 | ||
| No | 12 | 11 | 1 | 12 | 9 | 3 | ||
| BCLC staging | 0.080 | 1.000 | ||||||
| 0 | 15 | 11 | 4 | 15 | 12 | 3 | ||
| A | 59 | 55 | 4 | 59 | 49 | 10 | ||
| Prior TACE | 0.837 | 0.929 | ||||||
| Yes | 12 | 10 | 2 | 12 | 10 | 2 | ||
| No | 62 | 56 | 6 | 62 | 51 | 11 | ||
| GTV (mL) | 0.058 | 1.000 | ||||||
| ≤7.5 | 14 | 10 | 4 | 14 | 12 | 2 | ||
| >7.5 | 60 | 56 | 4 | 60 | 49 | 11 | ||
| Total liver volume (mL) | 0.155 | 0.008 | ||||||
| ≤1,162 | 25 | 20 | 5 | 25 | 16 | 9 | ||
| >1,162 | 49 | 46 | 3 | 49 | 45 | 4 | ||
| Normal liver volume (mL) | 0.295 | 0.015 | ||||||
| ≤1,148 | 29 | 24 | 5 | 29 | 20 | 9 | ||
| >1,148 | 45 | 42 | 3 | 45 | 41 | 4 | ||
| Number of lesions | 1.000 | 0.185 | ||||||
| 1 | 67 | 60 | 7 | 67 | 57 | 10 | ||
| >1 | 7 | 6 | 1 | 7 | 4 | 3 | ||
| Intrahepatic progression | 0.837 | 0.614 | ||||||
| Yes | 12 | 10 | 2 | 12 | 11 | 1 | ||
| No | 62 | 56 | 6 | 62 | 50 | 12 | ||
Abbreviations: BCLC, Barcelona Clinic Liver Cancer; CTP, Child–Turcotte–Pugh; ECOG, Eastern Cooperative Oncology Group; GTV, gross tumor volume; HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization.